Prognostic Factors for Luminal B-like Breast Cancer

Abstract

This study aimed to examine the prognostic factors of luminal B-like breast cancer. Clinical data of 695 luminal B-like breast cancer patients who had been treated in our hospital during the period of past 4.5 years were collected and analyzed. Estrogen receptor (ER), progesterone receptor (PgR), antigen identified by monoclonal antibody Ki-67 (Ki67) were immunohistochemically detected. Different cutoffs of ER, PgR, and Ki67 were evaluated. Pearson χ² test was performed to compare categorical parameters. Univariate and multivariate models were used to evaluate predictors of disease free survival (DFS). The results showed that patients who were younger, and had larger tumors, and more positive lymph nodes were more likely to receive neo-adjuvent chemotherapy (NAC). Patients with ER-positive tumors having <10% positive cells received more anthracycline- and taxane-based chemotherapy and less endocrine therapy than those with ER-positive tumors having ≥10% positive cells (P=0.004 and P=0.007, respectively); however, patients with ER-positive tumors having <10% positive cells experienced more recurrence (P<0.001). PgR expression levels were not associated with therapeutic schedule and DFS. Patients with tumor tissue Ki67 score ≥30% received more anthracycline- and taxane-based chemotherapy and had worse DFS than those with tumor tissue Ki67 score <30%. Univariate and multivariate analysis showed that clinical T stage, lymph nodes, ER, Ki67, and HER2 status were independent prognostic factors. In conclusion, ER-positive rate <10% and Ki67 score ≥30%, similar to higher clinical T stage, more metastatic lymph nodes, and HER2 positive status, may indicate a worse prognosis for luminal B-like breast cancer patients. Multi-center prospective trials with larger sample sizes are necessary for the continued perfection of our work.

Keywords

luminal B-like breast cancer / threshold / prognostic factor / estrogen receptor / Ki67

References

[1] GoldhirschA, WinerEP, CoatesAS. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol, 2013, 24(9): 2206-2223

[2] HammondME, HayesDF, DowsettM. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol, 2010, 28(16): 2784-2795

[3] VialeG, ReganMM, MaioranoE. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors—International Breast Cancer Study Group. J Clin Oncol, 2008, 26(9): 1404-1410

[4] VialeG, ReganMM, MaioranoE. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1–98. J Clin Oncol, 2007, 25(25): 3846-3852

[5] PratA, CheangMC, MartinM. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol, 2013, 31(2): 203-209

[6] PurdieCA, QuinlanP, JordanLB. Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study. Br J Cancer, 2014, 110(3): 565-572

[7] DunnwaldLK, RossingMA, LiCI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res, 2007, 9(1): R6

[8] DenkertC, von BudcziesJ, MinckwitzG. Strategies for developing Ki67 as a useful biomarker in breast cancer. Breast, 2015, 24: S67-S72

[9] PolleyMY, LeungSC, GaoD. An international study to increase concordance in Ki67 scoring. Modern pathology, 2015, 28(6): 778-786

[10] PolleyMY, LeungSC, McShaneLM. An international Ki67 reproducibility study. J Natl Cancer Inst, 2013, 105(24): 1897-1906

[11] AdesF, ZardavasD, Bozovic-SpasojevicI. Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. J Clin Oncol, 2014, 32(25): 2794-2803

[12] YuanJQ, WangSM, TangLL. Relative dose intensity and therapy efficacy in different breast cancer molecular subtypes: a retrospective study of early stage breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat, 2015, 151(2): 405-413

[13] FanC, OhDS, WesselsL. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med, 2006, 355(6): 560-569

[14] PaikS, TangG, ShakS. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol, 2006, 24(23): 3726-3734

[15] de RondeJJ, HannemannJ, HalfwerkH. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res Treat, 2010, 119(1): 119-126

[16] EssermanLJ, BerryDA, CheangMC. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat, 2012, 132(3): 1049-1062

[17] LipsEH, MulderL, de RondeJJ. Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics. Breast Cancer Res Treat, 2012, 131(3): 827-836

[18] LvM, LiB, LiY. Predictive role of molecular subtypes in response to neoadjuvant chemotherapy in breast cancer patients in Northeast China. Asian Pac J Cancer Prev, 2011, 12(9): 2411-2417

[19] GoldhirschA, WoodWC, CoatesAS. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol, 2011, 22(8): 1736-1747

[20] PrabhuJS, KorlimarlaA, DesaiK. A Majority of Low (1-10%) ER Positive Breast Cancers Behave Like Hormone Receptor Negative Tumors. J Cancer, 2014, 5(2): 156-165

[21] YiM, HuoL, KoenigKB. Which threshold for ER positivity? a retrospective study based on 9639 patients. Ann Oncol, 2014, 25(5): 1004-1011

[22] Early Breast Cancer Trialists’ Collaborative Group EBCTCGCD, JG. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet, 2011, 378(9793): 771-784

[23] DowsettM, AllredC, KnoxJ. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol, 2008, 26(7): 1059-1065

[24] Stuart-HarrisR, CaldasC, PinderSE. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast, 2008, 17(4): 323-334

[25] CoatesAS, WinerEP, GoldhirschA. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol, 2015, 268: 1533-1546

[26] LiJ, ZhangBN, FanJH. A nation-wide multicenter 10-year (1999-2008) retrospective clinical epidemiological study of female breast cancer in China. BMC Cancer, 2011, 11: 364